首頁 > 市場調查報告書 > 醫療設備

醫學影像診斷

市場調查報告書

商品編碼

1917793

臨床試驗診斷影像市場－2026-2031年預測

Clinical Trial Imaging Market - Forecast from 2026 to 2031

出版日期: 2026年01月06日 | 出版商:

Knowledge Sourcing Intelligence | 英文 144 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄

臨床試驗影像診斷市場預計將從 2025 年的 17.32 億美元成長到 2031 年的 26.07 億美元，複合年成長率為 7.05%。

臨床試驗診斷影像市場是生命科學產業中重要且不斷成長的細分市場，是現代藥物研發和療效評估的關鍵工具。該市場利用磁振造影（MRI）、電腦斷層掃描（CT）、正子斷層掃描（PET）和超音波等先進影像技術，為臨床研究中疾病進展和治療效果提供客觀、定量和縱向數據。其成長受多種因素驅動，包括臨床試驗複雜性的增加、慢性病盛行率的上升以及整個產業的大規模投資，這些因素共同作用，使診斷影像成為精準高效臨床研究的基礎。

市場擴張的關鍵促進因素是生物技術產業對以影像為中心的臨床研究的大量且不斷成長的投資。醫療保健成本的上升和對創新治療方法的關注推動了生物技術公司的激增，這直接促進了對先進影像終點的需求。從產業領導企業到新興企業，都在整合影像通訊協定，以降低研發風險、驗證生物學概念驗證並滿足新治療領域的監管要求。這一趨勢標誌著影像技術正從輔助工具轉變為臨床試驗設計的基本組成部分，尤其是在複雜的生物製劑和標靶治療。

全球癌症負擔日益加重，持續推動市場需求。腫瘤臨床試驗越來越依賴先進的成像技術進行患者分層、評估治療反應以及檢驗新的作用機制。隨著精準醫療和標靶治療的興起，精確的影像生物標記對於監測腫瘤生物學的細微變化至關重要，其應用也從簡單的解剖學測量發展到功能性和分子成像。影像技術在表徵癌症表現型和量化治療效果方面發揮關鍵作用，這使其在大多數腫瘤藥物研發項目中佔據核心地位，而這一趨勢仍在不斷發展。

此外，包括心血管疾病、代謝性疾病、神經系統疾病和腎臟疾病在內的多種慢性疾病的日益普遍，正在加速影像學在臨床試驗中的應用。對於這些疾病，影像學提供了一種非侵入性方法，可用於早期檢測、精準診斷以及靈敏地監測疾病的進展或消退。研究人員可以觀察器官和組織隨時間推移發生的病理變化，從而深入了解藥物作用機制和治療效果，尤其對於那些傳統終點指標進展緩慢或主觀性較強的疾病而言。這種能力對於開發治療長期慢性疾病的有效治療方法至關重要。

此外，全球臨床研究計劃規模的不斷擴大和複雜性的提升進一步推動了市場發展。在各個治療領域，採用影像學通訊協定的臨床試驗數量顯著增加。這得歸功於定量影像生物標記標準化以及臨床前和臨床影像學調查方法最佳化工作的發展。專注於產生可靠且可重複的影像學數據，能夠提高試驗質量，加快決策速度，並增加獲得監管部門核准的可能性。將影像學整合到大規模、跨國臨床試驗中，進一步證實了其在產生高度精確證據方面的既有價值。

從區域來看，北美預計將繼續佔據臨床試驗影像市場的主導地位。這一主導地位得益於多項結構性優勢，包括製藥和生物技術公司的高度集中、醫療保健和研究領域的巨額投入、需要先進治療研究的慢性疾病的高發生率，以及由臨床研究機構 (CRO) 和專業影像服務提供者組成的強大生態系統。持續的技術進步和支持創新研究設計的法規結構進一步鞏固了該地區在促進和傳播市場標準方面的關鍵作用。

在競爭格局中，專業服務供應商和技術公司為臨床試驗提供端到端的影像解決方案。這些解決方案涵蓋核心影像檢查實驗室服務和集中式影像分析，以及開發整合人工智慧 (AI) 和機器學習技術的專有軟體平台進行資料分析。各公司憑藉其在治療領域的專業知識、定量成像技術能力以及確保全球臨床試驗符合監管要求的能力而脫穎而出。這些服務對於以標準化和盲法的方式管理影像擷取、傳輸、分析和解讀等複雜流程至關重要。

總之，臨床試驗影像市場正經歷持續成長，其根本驅動力在於藥物研發需求的不斷演變。標靶治療的融合、慢性疾病中對客觀生物標記的需求以及生物技術產業的策略投資，共同鞏固了影像技術在臨床研究中作為關鍵成功因素的地位。未來市場的發展將受到定量影像生物標記進步、人工智慧在高級數據分析中的應用以及全球研究網路持續推進標準化需求的影響。對業界專家而言，重點仍是利用影像技術提高試驗效率、展現明確的治療價值並加速新治療方法惠及病患。

本報告的主要優勢：

深入分析：提供對主要和新興地區的深入市場洞察，重點關注客戶群、政府政策和社會經濟因素、消費者偏好、垂直行業和其他細分市場。
競爭格局：了解全球主要參與者的策略舉措，並了解透過正確的策略實現市場滲透的潛力。
市場促進因素與未來趨勢：探索推動市場的動態因素和關鍵趨勢，以及它們將如何塑造未來的市場發展。
可操作的建議：利用這些見解，在快速變化的環境中做出策略決策，並發現新的商機和收入來源。
受眾廣泛：適用於Start-Ups、研究機構、顧問公司、中小企業和大型企業，且經濟實惠。

企業如何使用我們的報告？

產業與市場分析、機會評估、產品需求預測、打入市場策略、地理擴張、資本投資決策、法規結構及影響、新產品開發、競爭情報

研究範圍：

2021年至2025年的歷史數據和2026年至2031年的預測數據
成長機會、挑戰、供應鏈前景、法規結構與趨勢分析
競爭定位、策略和市場佔有率分析
按業務板塊和地區（包括國家）分類的收入和預測評估
公司概況（策略、產品、財務資訊、關鍵發展等）

介紹
北美洲
- 美國
- 加拿大
- 墨西哥
南美洲
- 巴西
- 阿根廷
- 其他
歐洲
- 德國
- 法國
- 英國
- 西班牙
- 其他
中東和非洲
- 沙烏地阿拉伯
- 阿拉伯聯合大公國
- 以色列
- 其他
亞太地區
- 中國
- 印度
- 日本
- 韓國
- 印尼
- 泰國
- 其他

第10章競爭格局與分析

主要企業和策略分析
市佔率分析
合併、收購、協議和合作
競爭對手儀錶板

第11章公司簡介

IXICO plc
Resonance Health
Radiant Sage LLC
Medpace Holdings, Inc
WCG Clinical
Koninklijke Philips NV
Median Technologies
Perceptive
Clario
Qmenta

第12章附錄

貨幣
先決條件
基準年和預測年時間表
相關人員的主要收益
調查方法
簡稱

簡介目錄

Product Code: KSI061615767

Clinical Trial Imaging Market is projected to expand at a 7.05% CAGR, attaining USD 2.607 billion in 2031 from USD 1.732 billion in 2025.

The clinical trial imaging market is a critical and expanding segment within the life sciences industry, serving as an indispensable tool for modern drug development and therapeutic evaluation. This market encompasses the use of advanced imaging modalities-such as MRI, CT, PET, and ultrasound-to provide objective, quantitative, and longitudinal data on disease progression and treatment efficacy within clinical research. Its growth is propelled by a confluence of factors including the rising complexity of clinical trials, the increasing prevalence of chronic diseases, and significant sector-wide investments, positioning imaging as a cornerstone of precise and efficient clinical research.

A primary driver of market expansion is the substantial and growing investment from the biotechnology sector into imaging-centric clinical research. The proliferation of biotechnology companies, fueled by increased healthcare expenditure and a focus on innovative therapies, has directly increased demand for sophisticated imaging endpoints. These companies, ranging from established leaders to emerging entities, are integrating imaging protocols to de-risk development, demonstrate biological proof-of-concept, and satisfy regulatory requirements for novel therapeutic classes. This trend signifies a shift where imaging is no longer a supplementary tool but a foundational component of clinical trial design, particularly for complex biological and targeted therapies.

The escalating global burden of cancer remains a powerful catalyst for market demand. Oncology clinical trials increasingly rely on advanced imaging for patient stratification, treatment response assessment, and the evaluation of novel mechanisms of action. The shift towards personalized medicine and targeted therapies necessitates precise imaging biomarkers to monitor subtle changes in tumor biology, moving beyond simple anatomic measurements to functional and molecular imaging. The critical role of imaging in characterizing cancer phenotypes and quantifying therapeutic impact ensures its central position in the vast majority of oncological drug development programs, a trend that continues to intensify.

Furthermore, the growing prevalence of a broad spectrum of chronic diseases-including cardiovascular, metabolic, neurological, and renal disorders-is accelerating the adoption of clinical trial imaging. For these conditions, imaging provides non-invasive methods for early detection, precise diagnosis, and sensitive monitoring of disease progression or regression. It enables researchers to visualize pathological changes in organs and tissues over time, offering invaluable insights into a drug's mechanism of action and therapeutic benefit in diseases where traditional endpoints may be slow to manifest or subjective. This capability is crucial for developing effective interventions for long-term chronic conditions.

The market is further stimulated by the increasing scale and sophistication of global clinical research projects. There is a marked rise in the number of trials incorporating imaging protocols across diverse therapeutic areas. This is supported by initiatives aimed at standardizing quantitative imaging biomarkers and optimizing imaging methodologies for both preclinical and clinical settings. The focus on generating robust, reproducible imaging data enhances trial quality, facilitates faster decision-making, and improves the likelihood of regulatory success. The integration of imaging into large-scale, multinational trials underscores its established value in generating high-fidelity evidence.

From a regional perspective, North America is projected to maintain a dominant share of the clinical trial imaging market. This leadership is attributed to several structural advantages: a high concentration of pharmaceutical and biotechnology corporations, substantial healthcare and research expenditure, a significant prevalence of chronic diseases necessitating advanced therapeutic research, and a robust ecosystem of clinical research organizations (CROs) and imaging specialty providers. Continuous technological advancements and supportive regulatory frameworks for innovative trial designs further consolidate the region's pivotal role in driving market standards and adoption.

The competitive landscape features specialized service providers and technology companies that offer end-to-end imaging solutions for clinical trials. These range from core imaging laboratory services and centralized image analysis to the development of proprietary software platforms incorporating artificial intelligence and machine learning for data analytics. Companies are distinguished by their therapeutic area expertise, technological capabilities in quantitative imaging, and their ability to ensure regulatory compliance across global trials. Their services are critical in managing the complexity of image acquisition, transfer, analysis, and interpretation in a standardized and blinded manner.

In conclusion, the clinical trial imaging market is experiencing sustained growth, fundamentally driven by the evolving needs of drug development. The convergence of targeted therapeutic modalities, the demand for objective biomarkers in chronic diseases, and the strategic investments from the biotech sector are cementing imaging's role as a critical success factor in clinical research. Future market evolution will be shaped by advancements in quantitative imaging biomarkers, the integration of artificial intelligence for enhanced data analysis, and the ongoing need for greater standardization across global research networks. For industry experts, the focus remains on leveraging imaging to improve trial efficiency, demonstrate definitive therapeutic value, and accelerate the delivery of new treatments to patients.

Key Benefits of this Report:

Insightful Analysis: Gain detailed market insights covering major as well as emerging geographical regions, focusing on customer segments, government policies and socio-economic factors, consumer preferences, industry verticals, and other sub-segments.
Competitive Landscape: Understand the strategic maneuvers employed by key players globally to understand possible market penetration with the correct strategy.
Market Drivers & Future Trends: Explore the dynamic factors and pivotal market trends and how they will shape future market developments.
Actionable Recommendations: Utilize the insights to exercise strategic decisions to uncover new business streams and revenues in a dynamic environment.
Caters to a Wide Audience: Beneficial and cost-effective for startups, research institutions, consultants, SMEs, and large enterprises.

What do businesses use our reports for?

Industry and Market Insights, Opportunity Assessment, Product Demand Forecasting, Market Entry Strategy, Geographical Expansion, Capital Investment Decisions, Regulatory Framework & Implications, New Product Development, Competitive Intelligence

Report Coverage:

Historical data from 2021 to 2025 & forecast data from 2026 to 2031
Growth Opportunities, Challenges, Supply Chain Outlook, Regulatory Framework, and Trend Analysis
Competitive Positioning, Strategies, and Market Share Analysis
Revenue Growth and Forecast Assessment of segments and regions including countries
Company Profiling (Strategies, Products, Financial Information, and Key Developments among others.)

Clinical Trial Imaging Market Segmentation

By Offerings
Solutions
Services
By Technique
MRI (Magnetic Resonance Imaging)
CT (Computed Tomography)
PET (Positron Emission Tomography)
Ultrasound
Others
By Application
Oncology
Cardiology
Gastroenterology
Neurology
Pediatrics
Others
By End-User
Hospitals & Clinics
Diagnostics Centers
Others
By Geography
North America
United States
Canada
Mexico
South America
Brazil
Argentina
Others
Europe
Germany
France
United Kingdom
Spain
Others
Middle East and Africa
Saudi Arabia
UAE
Israel
Others
Asia Pacific
China
India
Japan
South Korea
Indonesia
Thailand
Others

1. EXECUTIVE SUMMARY

2. MARKET SNAPSHOT

2.1. Market Overview
2.2. Market Definition
2.3. Scope of the Study
2.4. Market Segmentation

3. BUSINESS LANDSCAPE

3.1. Market Drivers
3.2. Market Restraints
3.3. Market Opportunities
3.4. Porter's Five Forces Analysis
3.5. Industry Value Chain Analysis
3.6. Policies and Regulations
3.7. Strategic Recommendations

4. TECHNOLOGICAL OUTLOOK

5. CLINICAL TRIAL IMAGING MARKET BY OFFERINGS

5.1. Introduction
5.2. Solutions
5.3. Services

6. CLINICAL TRIAL IMAGING MARKET BY TECHNIQUE

6.1. Introduction
6.2. MRI (Magnetic Resonance Imaging)
6.3. CT (Computed Tomography)
6.4. PET (Positron Emission Tomography)
6.5. Ultrasound
6.6. Others

7. CLINICAL TRIAL IMAGING MARKET BY APPLICATION

7.1. Introduction
7.2. Oncology
7.3. Cardiology
7.4. Gastroenterology
7.5. Neurology
7.6. Pediatrics
7.7. Others

8. CLINICAL TRIAL IMAGING MARKET BY END-USER

8.1. Introduction
8.2. Hospitals & Clinics
8.3. Diagnostics Centers
8.4. Others

9. CLINICAL TRIAL IMAGING MARKET BY GEOGRAPHY

9.1. Introduction
9.2. North America
- 9.2.1. USA
- 9.2.2. Canada
- 9.2.3. Mexico
9.3. South America
- 9.3.1. Brazil
- 9.3.2. Argentina
- 9.3.3. Others
9.4. Europe
- 9.4.1. Germany
- 9.4.2. France
- 9.4.3. United Kingdom
- 9.4.4. Spain
- 9.4.5. Others
9.5. Middle East and Africa
- 9.5.1. Saudi Arabia
- 9.5.2. UAE
- 9.5.3. Israel
- 9.5.4. Others
9.6. Asia Pacific
- 9.6.1. China
- 9.6.2. India
- 9.6.3. Japan
- 9.6.4. South Korea
- 9.6.5. Indonesia
- 9.6.6. Thailand
- 9.6.7. Others